Zan Fleming
co-founder, president and CEO
Advisory Board
Melior Discovery
Australia
Biography
Dr. Alexander "Zan" Fleming is co-founder, president and CEO of Kinexium, LLC, a cardiometabolic strategic consulting organization. He also sits on over a dozen clinical advisory boards for major pharma and biotech companies. Previously, he served as chief medical officer of Boston Medical Technologies and chief scientific officer of Ingenix Pharmaceutical Services - A UnitedHealth Group Company. For 12 years, he served as reviewer and supervisory medical officer at the FDA, as head of the metabolic group. He has extensive clinical experience and regulatory responsibility in the therapeutic areas of diabetes, other metabolic and endocrine disorders, growth and development, nutrition, lipid-lowering compounds, and reproductive indications. He led reviews of landmark approvals including those of the first statin, insulin analogs, metformin, PPAR-agonist, and growht hormone for non-GH deficiency indications. He was responsible for the regulation of the earliest biotech products including human insulin and growth hormone. He also helped to shape a number of FDA policies and practicies related to therapeutic review and regulatory communication.
Research Interest
Medicine
